Edgar Filing: Emergent BioSolutions Inc. - Form 4/A

Emergent BioSolutions Inc. Form 4/A November 10, 2014

November 1	0, 2014												
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION										OMB APPROVAL			
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287				
Check this box							Expires:	January 31, 2005					
subject to Section 1 Form 4 o	F CHAN	F CHANGES IN BENEFICIAL OWNERS SECURITIES					Estimated a burden hou response	average rs per					
Form 5 obligatio may cont <i>See</i> Instru 1(b).	inue. Section	7(a) of the		ility Hold	ling Com	pany	Act of	e Act of 1934, f 1935 or Sectio 40	n				
(Print or Type I	Responses)												
1. Name and Address of Reporting Person <u>*</u> El-Hibri Fuad			Symbol	2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]				5. Relationship of Reporting Person(s) to Issuer					
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Chec				k all applicable)						
2273 RESE 400	ARCH BLVD	., SUITE	(Month/D 08/26/20	•				X Director X Officer (give below)	e titleOtho below) Chairman	6 Owner er (specify			
Filed(Mo				f Amendment, Date Original ed(Month/Day/Year) /27/2014				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
ROCKVILI	LE, MD 20850		00/2//20	J1 -				Form filed by M Person					
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	ecurit	ies Acq	equired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)	2. Transaction 1 (Month/Day/Yo	ear) Executi any	emed on Date, if /Day/Year)	3. Transactic Code (Instr. 8) Code V	4. Securit on(A) or Di (D) (Instr. 3, 4)	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
Common Stock	08/26/2014			S	70,796 (1) (2)	D		2,069,243 <u>(3)</u>	D				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title o Derivativ Security (Instr. 3)	ve Conversion or Exercise	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Titl Amou Under Secur (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Emergent BioSolutions Inc. - Form 4/A

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
El-Hibri Fuad 2273 RESEARCH BLVD., SUITE 400 ROCKVILLE, MD 20850	Х	Х	Chairman			
Signatures						
/s/ Carl A. Valenstein, attorney-in-fact	11/10/2	2014				

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This amendment to the Form 4 previously filed on August 27, 2014 is being filed to correct an understatement of the number of securities disposed of in the transaction from "70,769" to "70,796" and to correct the transaction code from "F" to "S".
- (2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2014.

Mr. El-Hibri's direct holdings include restricted stock units granted under the 2nd Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan and the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. Mr. El-Hibri's

(3) restricted stock units vest in equal annual installments beginning on the anniversary of the grant date, assuming continued service with the company. Each restricted stock unit represents the right of the reporting person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.